Back to Journals » The Application of Clinical Genetics » Volume 19

Routine Excision, Rare Diagnosis: Solitary Neurofibroma Prompting NF1 Screening in an Adolescent

Authors Alquaimi MM ORCID logo

Received 25 June 2025

Accepted for publication 30 January 2026

Published 6 February 2026 Volume 2026:19 549653

DOI https://doi.org/10.2147/TACG.S549653

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Prof. Dr. Martin Maurer



Manal Mubarak Alquaimi

Department of Surgery, King Faisal University, Al-Ahsa, Saudi Arabia

Correspondence: Manal Mubarak Alquaimi, Department of Surgery, King Faisal University, Al-Ahsa, Saudi Arabia, Email [email protected]

Abstract: A solitary plexiform neurofibroma in a 15-year-old girl prompted an unexpected referral for neurofibromatosis type 1 (NF1) evaluation. Initially excised under the impression of a lipoma, the lesion’s histopathology revealed neural origin features with strong S100 and CD34 positivity. Dermatologic examination uncovered multiple café-au-lait macules, and subsequent referral to neurology raised clinical suspicion for NF1. This case emphasizes how incidental histological findings in a benign-appearing lesion can serve as the first clinical clue of a genetic disorder, triggering appropriate multidisciplinary evaluation.

Plain Language Summary: A 15-year-old girl had a small, soft lump on her upper back that looked like a harmless fatty growth (lipoma). After removing it through a minor surgery, doctors found that it was actually a type of nerve tumor called a neurofibroma. This discovery led to further evaluations that showed she might have a genetic condition called neurofibromatosis type 1 (NF1), even though she had no other obvious symptoms. This case shows how something that seems simple can be the first clue to a bigger health issue and why it’s important to look deeper when the results are unexpected.

Keywords: neurofibromatosis type 1, plexiform neurofibroma, solitary neurofibroma, genetic screening, adolescent, histopathology

Introduction

Neurofibromatosis type 1 (NF1) is a common autosomal dominant neurocutaneous disorder characterized by cutaneous, neurological, and skeletal manifestations. Though often diagnosed in early childhood, some individuals may present with subtle or overlooked signs, delaying recognition. Plexiform neurofibromas are considered pathognomonic for NF1, but may occasionally present in isolation. Identifying such tumors incidentally through histology can prompt genetic evaluation and early diagnosis of NF1, offering an opportunity for timely surveillance and family counseling.1–3

Case Presentation

A 15-year-old female presented with a 3×3 cm soft, mobile, painless upper back mass noted for one year. It was excised under local anesthesia due to cosmetic concerns. Histopathology confirmed plexiform neurofibroma, with characteristic spindle cell features (Figures 1–4) and supportive S100 and CD34 positivity (Figures 5 and 6).

Figure 1 Low power magnification (10X) showing a moderately cellular spindle cell lesion with focal edematous stroma.

Figure 2 Low power magnification (10X) with another view of spindle cell areas.

Figure 3 High power magnification (20X) showing spindle cells with wavy nuclei and eosinophilic cytoplasm.

Figure 4 High power magnification (20X) confirming no atypia or necrosis.

Figure 5 S100 immunohistochemistry showing diffuse nuclear positivity.

Figure 6 CD34 immunohistochemistry demonstrating a lattice-like network positivity.

Following histologic diagnosis, the patient was re-evaluated, revealing multiple café-au-lait macules. There was no personal or family history of NF1. She was referred to dermatology and neurology for NF1 evaluation and genetic counseling was initiated.

Discussion

This case illustrates how a routine excision of a lesion presumed to be benign led to the first clinical suspicion of NF1. The incidental histological finding of a plexiform neurofibroma in a child should prompt dermatological and neurological assessment for NF1, especially in the presence of pigmentary skin changes. While genetic testing was pending at the time of report, the presence of both a plexiform neurofibroma and café-au-lait macules is sufficient to meet clinical criteria for NF1.

Early identification is crucial in NF1, as complications may include optic gliomas, learning disabilities, skeletal abnormalities, and increased tumor risk. Early referral allows for proactive monitoring and intervention.4,5

Conclusion

Solitary plexiform neurofibroma can be an early or even the first clinical indicator of NF1. This case reinforces the importance of correlating unexpected histological diagnoses with dermatologic and neurologic signs, prompting timely referral and surveillance.

Data Sharing Statement

All data generated or analyzed during this study are included in this published article. Further inquiries can be directed to the corresponding author.

Ethics and Consent Statements

Institutional review board approval was not required for publication of this case report. Informed consent for publication was obtained from the patient’s guardian.

Funding

No external funding was received.

Disclosure

The author declares no conflicts of interest in this work.

References

1. Ferner RE. Neurofibromatosis 1 and neurofibromatosis 2: a twenty-first century perspective. Lancet Neurol. 2007;6(4):340–4. doi:10.1016/S1474-4422(07)70075-3

2. Jett K, Friedman JM. Clinical and genetic aspects of neurofibromatosis 1. Genet Med. 2010;12(1):1–11. doi:10.1097/GIM.0b013e3181bf15e3

3. Hirbe AC, Gutmann DH. Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol. 2014;13(8):834–843. doi:10.1016/S1474-4422(14)70063-8

4. Peltonen J, Jaakkola S, Virtanen I, Peltonen S. Schwann cell characteristics in neurofibromas. Ann Med. 1995;27(5):401–409.

5. Tucker T, Friedman JM. Pathogenesis of hereditary tumors: beyond the “two-hit” hypothesis. Clin Genet. 2002;62(5):345–357. doi:10.1034/j.1399-0004.2002.620501.x

Creative Commons License © 2026 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms and incorporate the Creative Commons Attribution - Non Commercial (unported, 4.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.